Author: H. Lynn Starr, MD, McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA Two analyses from the Formal Observation of Concerta versus Strattera (FOCUS) trial—a comparison of osmotic methylphenidate (OROS® MPH/Concerta®, McNeil) and atomoxetine (Eli Lilly)—showed surprising symptom improvement and responder rate benefits over time with OROS® MPH in children with attention deficit/hyperactivity disorder (ADHD).
Author: Andre Galinowski, Doctor of Psychiatry, Service Hospitalo-Universitaire De Sante Mentale & De Therapeu-tique, Paris, France A naturalistic study of escitalopram (Lexapro medication, Forest) in depressed patients with concomitant morbid anxiety showed satisfactory control for symptoms of both conditions, according to a new study. The trial included both the high comorbidity rate for depression and […]
Emergent and Worsening Suicide Ideation in Trials of Pediatric Paroxetine for Depression Author: Regan Fong, PhD, GlaxoSmithKline, King of Prussia, PA In September, 2004, the Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended “black-box” warnings for antidepressants after finding a 2.15 overall risk ratio with users of paroxetine (GlaxoSmithKline), compared with non-users, […]
Treatment Options From 65% to 75% of cases of depression are treatable; depression can be fatal in 15% of cases if it remains untreated. The earlier the intervention in primary care, the earlier the remission. A “watch-and-wait” period of no more than two weeks for bereavement is acceptable. The lesser the intensity of the initial […]
The possibility of depression is always present in the clinical encounter. The rate at which primary health care providers recognize clinical depression varies widely: from 19% to 94%. Cognitive impairment and other medical comorbidities often hinder the ability to arrive at an accurate diagnosis. Yet elderly patients overwhelmingly prefer the care of their primary physician […]
Depression can be classified into three major types: • early-onset, with longstanding psychobiological vulnerability (i.e., positive family history and prior episodes) • late-onset, associated with stressful life events • late-onset, with underlying vascular pathology
The percentage of elderly people continues to grow in America, with the “oldest old” now recognized as the fastest-growing segment. Nearly 7 million of the 35 million Americans (15%-25%) 65 years of age or older have depression, and 1 million of the 7 million have major depression; the overall prevalence is 1% (1.4% in women, […]